Where does JelliSee Ophthalmics Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), JelliSee Ophthalmics Inc. ranks #36,018 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does JelliSee Ophthalmics Inc. hold?

JelliSee Ophthalmics Inc. holds 7 US utility patents granted between 2021 and 2024, spanning 4 technology areas.

What is JelliSee Ophthalmics Inc.'s Innovation Score?

JelliSee Ophthalmics Inc. has an Innovation Score of 41.8 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is JelliSee Ophthalmics Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for JelliSee Ophthalmics Inc..

What does claim depth mean for JelliSee Ophthalmics Inc.'s patents?

JelliSee Ophthalmics Inc.'s patents average 12.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the JelliSee Ophthalmics Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

JelliSee Ophthalmics Inc.

Q: What technology areas does JelliSee Ophthalmics Inc. focus on?

JelliSee Ophthalmics Inc.'s top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 7 patents, ranking #891 of 3,082 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Jellisee ranks #36,018 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#36,018
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.8/100): 12.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R36018 · US Corporation #36,018 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #36,018/49,997
PHOTO-FINISH Janus Technology…
CPC-NARROW A61F · 4 areas
INNOV-PAR 41.8/100
CLAIMS-RICH 12.6 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2024 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Janus Technology Solutions, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Jellisee’s 41.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (17%) Velocity 20.0 pts (48%) Breadth 7.1 pts (17%) Claim depth 7.5 pts (18%)

Qualcomm Incorporated · highest

85
JelliSee Ophthalmics · this assignee

42
3D Lighting… · lowest

7

What this shows Jellisee's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Jellisee?

Each dot is one of Jellisee’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Jellisee’s own 12.6 claims/patent is at or below the 16.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Jellisee vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Jellisee's grants concentrate

JelliSee Ophthalmics Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2021. By volume, Jellisee sits between Janus Technology Solutions, LLC and Jessem Tool Corporation.

Jellisee's three-year grant acceleration

JelliSee Ophthalmics Inc. shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Janus Technology…

7
Japan Elastomer

7
Jasper Design Aut…

7
Jaybridge Robotics

7
Jena-optronik

7
Jenesis Internati…

7
Jergens

7
Jessem Tool

7
Jellisee Ophthalm… ◀

7

What this shows JelliSee holds 7 patents at rank #36,030, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near JelliSee

By rank, the assignees closest to #36,030 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in JelliSee's primary technology class.

Jellisee's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

JelliSee Ophthalmics Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	14.3%
2022	4	57.1%
2023	1	14.3%
2024	1	14.3%

Which technologies does JelliSee Ophthalmics Inc. patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 7

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 4

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 3

C08L - Compositions OF Macromolecular Compounds 3

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

JelliSee Ophthalmics Inc.'s patent record in context - here's where to go next.

JelliSee Ophthalmics Inc.'s lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #36,018 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare JelliSee Ophthalmics Inc. against Janus Technology Solutions, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.